EY Snapshot into UEFA’s newly introduced Club Licensing and Financial Sustainability Regulations


Featured insights

Sailboat sailing towards the horizon at sunset

EY Biotech Report 

The Global Biotech Report — “Beyond Borders” 2022 covers key developments in 2021. One common theme stands out: Switzerland punches well above its weight when it comes to biotech innovation. 

Global Biotech - Powered by Innovation

Man at the Beach for Surfing

Digital Solution Store

You provide the challenge — we’ll provide the solution. We help you navigate the complex waters of technical transformation with sophisticated solutions designed, developed and delivered by seasoned EY experts. Whatever digital quandaries you face, we’ll find an approach tailored to your needs. 

Discover more

factory layered frame

EY Sustainability Report 2021 

With our EY Switzerland Sustainability Report 2021 we provide insights on the impact we have on our people, clients, society and the environment.

EY Sustainability Report 2021

Work Reimagined

EY believes in a future world of work that empowers your people, organization and customers to create long-term value. Leveraging technology, talent and our global reach, EY helps you design sustainable new people strategies that work for you. 



EY is committed to making business work for sustainability and sustainability work for business. We can help you create new value from the innovation opportunity of our lifetime.


Direct to your mailbox

Stay up to date with our latest insights.


Featured media releases

Direct Investment in Europe: The economy is recovering slowly from the pandemic – Switzerland remains attractive

Zurich, May 31 2022 – Switzerland remains a popular location for investors: With a total of 75 direct investments made in 2021, it ranks 16th overall in Europe. Despite a slight decline in relation to the size of the country, this is a very good ranking. Switzer-land ranked 14th in 2020 and 17th in 2019. This is shown by the audit and consulting firm EY’s latest study of investment projects by foreign companies in Europe.

31 May 2022

Swiss Biotech Report 2022 shows sector again performs exceptionally at all levels

During 2021, Switzerland’s life sciences sector again played a major role in combating the COVID pandemic with two Swiss based companies developing in partnerships effective Covid-specific therapeutics (Humabs BioMed/Vir Biotechnology and Molecular Partners/Novartis). In addition, Swiss life science companies also continued their work developing innovative solutions for other high unmet medical needs. This resulted in another year of very strong capital investments totaling CHF 3.33B from domestic and international sources and R&D investments aggregating to a new record of CHF 2.56B. The latest edition of the Swiss Biotech Report launched today by the Swiss Biotech Association in conjunction with EY and seven other partner organizations provides an analysis of the 2021 biotech funding as well as other 2021 key ratios and statistics compared to prior years.

3 May 2022

A positive working atmosphere is the most important factor for Swiss millennials – salary is losing importance

Zurich, 26. April 2022 – The world of work has changed fundamentally due to the pandemic and, with it, the demands of employees have shifted – this also applies to millennials. When looking for a job, they are not interested in money – at least not just money.

27 Apr 2022